CEO Kristen Fortney emphasized that this collaboration underscores the value of BioAge's platform and aims to discover novel therapeutic targets to enhance health outcomes.

Importantly, the partnership allows BioAge to continue developing its existing programs independently while expanding its portfolio of potential therapies.

This collaboration also highlights the significance of lifestyle factors, particularly exercise, in promoting healthy aging and aims to identify molecular factors that could lead to new therapeutic interventions.

BioAge Labs has announced a multi-year research collaboration with Novartis, aimed at exploring the biological mechanisms behind age-related diseases and the benefits of exercise.

The collaboration has a total potential value exceeding $530 million, indicating strong financial support for innovative research and development efforts.

This partnership follows BioAge's recent IPO, which raised $198 million and valued the company at approximately $606 million, highlighting the pharmaceutical industry's growing interest in BioAge's drug discovery approach.

The collaboration comes on the heels of BioAge halting a Phase 2 obesity trial due to safety concerns, illustrating the challenges faced in biotech innovation.

Michaela Kneissel from Novartis expressed enthusiasm about leveraging human longevity data alongside exercise biology to create new treatment options for aging-related diseases.

The partnership includes up to $20 million in upfront payments and research funding, with the possibility of an additional $530 million contingent upon achieving specific milestones.

BioAge's extensive human longevity datasets, some tracking individuals for up to 50 years, will be combined with Novartis' expertise in exercise biology to identify new therapeutic targets.